10.13.25 -- On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D.

A cost-effective approach with a comprehensive AAV analytical package holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Discover how a company is overcoming purification challenges and advancing scalable, GMP-ready LVV manufacturing for gene and cell therapies.

Investigate the development work involved for the individual technologies that make up an innovative and scalable, chemical-free continuous viral vector production platform.

Consider how Buoyancy Activated Cell Sorting (BACS) can streamline T cell isolation, reduce costs, and enhance CAR T and TCR cell therapy manufacturing. Access the full study to learn more.

Addressing the complexities of viral vector manufacturing through strategic internalization, advanced technologies, and regulatory excellence is crucial for the future of gene therapies.

What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.

CAR-T cell therapy is poised to transform cancer care in India, with new initiatives aiming to make this breakthrough treatment both clinically feasible and financially accessible.